| Abstract | Patients with mammary dysplasia (17 patients) and controls (6 patients) were treated in a double-blind study with alpha-tocopherol acetate (600 units/day). Determination of serum alpha-tocopherol, estradiol, estriol., and progesterone were made from blood samples collected on Day 21 of the menstrual cycle before and during therapy. Eight-eight % of patients showed clinical response to therapy. Serum alpha-tocopherol concentrations rose after therapy in patients and controls. Serum estradiol and progesterone concentration were not statistically different in patients or controls after therapy, although patients showed a trend toward increased serum progesterone concentration. However, the ratio of progesterone to estradiol, which is abnormal in mammary dysplasia patients, rose from 30 +/- 7 (S.E.) to 53 +/- 11 in patients after alpha-tocopherol therapy (p less than 0.05). Control patients showed no significant change in progesterone/estradiol ratio. Results of this study indicate that alpha-tocopherol therapy may correct an abnormal progesterone/estradiol ratio in patients with mammary dysplasia, with implications on reducing future risk for malignant breast disease. |
| Authors | R S London, G S Sundaram, M Schultz, P P Nair, P J Goldstein |
| Journal | Cancer research
(Cancer Res)
Vol. 41
Issue 9 Pt 2
Pg. 3811-3
(Sep 1981)
ISSN: 0008-5472 UNITED STATES |
| PMID | 7020937
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
| Chemical References |
- Vitamin E
- Estriol
- Estradiol
- Progesterone
|
| Topics |
- Adolescent
- Adult
- Breast Diseases
(drug therapy)
- Breast Neoplasms
(prevention & control)
- Clinical Trials as Topic
- Double-Blind Method
- Endocrine Glands
(drug effects, metabolism)
- Estradiol
(blood)
- Estriol
(blood)
- Female
- Humans
- Menstruation
- Precancerous Conditions
(drug therapy)
- Progesterone
(blood)
- Vitamin E
(blood, therapeutic use)
|
